BMS-90011 is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Squamous Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 5 clinical trials, of which 1 was completed, and 4 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of BMS-90011’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for BMS-90011 is expected to reach an annual total of $12 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

BMS-90011 Overview

BMS-90011 is under development for the treatment of relapsed and refractory Non-Hodgkin Lymphoma, metastatic castration-resistant prostate cancer (mCRPC), relapsed and refractory solid tumors including neuroendocrine carcinoma, squamous non-small cell lung cancer, small-cell lung cancer, and non-Hodgkin's lymphomas, relapsed and refractory acute myeloid leukemia (AML), acute myeloid leukemia, diffuse large B-cell lymphoma, follicular lymphoma (FL), marginal zone B-cell Lymphoma s including nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, extranodal marginal zone B-cell lymphoma. It is administered orally. The drug candidate acts by targeting Lysine-specific demethylase 1 (LSD-1).

Bristol-Myers Squibb Overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

The company reported revenues of (US Dollars) US$46,159 million for the fiscal year ended December 2022 (FY2022), a decrease of 0.5% over FY2021. The operating profit of the company was US$9,665 million in FY2022, compared to an operating profit of US$8,615 million in FY2021. The net profit of the company was US$6,327 million in FY2022, compared to a net profit of US$6,994 million in FY2021.

For a complete picture of BMS-90011’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.